Literature DB >> 10709850

Angiotensin converting enzyme: history and relevance.

S H Ferreira1.   

Abstract

The renin angiotensin system (RAS) is now recognized as the body's most powerful hormone system for controlling renal hemodynamics and sodium excretion and, therefore, body fluid volumes and arterial pressure. The discovery of angiotensin converting enzyme inhibitors (ACEi) was a keystone for the understanding of the significance of the RAS since ACEi proved to be effective in controlling hypertension and heart failure and in preventing the development of the vascular injury of chronic diseases like scleroderma and diabetes mellitus. The success of ACEi stimulated the research into inhibitors of other actors of the RAS like renin or angiotensin receptor antagonists. It is not often realized that the discovery of ACEi owes a great deal to basic research in which the venom of a Brazilian viper, Bothrops Jararaca, was instrumental for the discovery of bradykinin by Rocha e Silva and the bradykinin potentiating factor. This article reviews the contribution of the converting enzyme inhibitors for the demonstration of the relevance of the RAS to several human pathologies.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10709850     DOI: 10.1016/s0146-0005(00)80046-4

Source DB:  PubMed          Journal:  Semin Perinatol        ISSN: 0146-0005            Impact factor:   3.300


  2 in total

1.  Effects of perindopril on soluble intercellular adhesion molecule-1 in patients with congestive heart failure.

Authors:  X-M Wang; Y Li; H-F Li; F Liu; G-L Jia
Journal:  Heart       Date:  2002-10       Impact factor: 5.994

2.  Coronavirus uses as binding site in humans angiotensin-converting enzyme 2 functional receptor that is involved in arterial blood pressure control and fibrotic response to damage and is a drug target in cardiovascular disease. Is this just a phylogenetic coincidence?

Authors:  Michele M Ciulla
Journal:  J Med Virol       Date:  2020-03-26       Impact factor: 2.327

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.